Primary Endpoint and Analysis Model for Prevention Trials with Participants with Preclinical AD: Lessons Learned from the DIAN‐TU Platform Trial

Abstract

Background: With the emerge of effective treatments for mild cognitive impairment and moderate Alzheimer's disease (AD), there's a shift towards evaluating these interventions in individuals with preclinical AD or those with elevated amyloid levels in prevention trials.